RE: When the facts change....22 Nov 2023 11:46
Dug,
You can spin your posts any way you like but the fact has changed is your posting negatively and talking down the shares because you bottled it here (for whatever reason that might have been).
Everyone I know that bought into OBD was buying in for the USA PSE testing and then for the UK CIRT testing.
No one was really expecting anything form the NHS for all the reasons you and other have highlighted many times on here.
NHS is a slow moving beast and will take it's own sweet time to see if it wants to adopt the PSE test as will Cancer UK, from Cancer UK feedback they have already stated their position long ago that it's too early for them due to lack of mass testing results, that has never been in dispute and I have that on their email from 4th October 2023:
Firstly thank you very much for your email, we are starting to get queries on this since the story broke, and appreciate how this could sound like fantastic news but actually there is work to be done. I think the answer is, it's a bit of both at the moment. I've put an initial response below from our research team, but we are formulating a response for our website and to ensure our Specialists Nurses (who are available for you to speak to or message) are briefed.
Our interim stance is:
We welcome promising new research like this into new possible tests which could help diagnose men accurately and at an earlier stage. However, we now need to see this tested in far greater numbers of men before we can determine just how effective this approach could be.
Just following up on the above, I think the issue is there's not going to be one eureka moment with prostate cancer, more likely iterative steps and developments along the way towards a national screening programme. Appreciate this is frustrating at the moment. If you are not already, I'd subscribe to our communications and keep an eye on our social media channels for a more formal and in-depth response.
Cheers
Dan
Daniel Richards (he/him)
Brand Partnerships Manager
Prostate Cancer UK
Sign In
Follow the stocks
